849 related articles for article (PubMed ID: 18852116)
21. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Hiles JJ; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib (BAY 43-9006): review of clinical development.
Ng R; Chen EX
Curr Clin Pharmacol; 2006 Sep; 1(3):223-8. PubMed ID: 18666747
[TBL] [Abstract][Full Text] [Related]
23. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Jilaveanu L; Zito C; Lee SJ; Nathanson KL; Camp RL; Rimm DL; Flaherty KT; Kluger HM
Clin Cancer Res; 2009 Feb; 15(3):1076-85. PubMed ID: 19188183
[TBL] [Abstract][Full Text] [Related]
24. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
Heim M; Scharifi M; Zisowsky J; Jaehde U; Voliotis D; Seeber S; Strumberg D
Anticancer Drugs; 2005 Feb; 16(2):129-36. PubMed ID: 15655409
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
26. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
LaRocca RV; Hicks MD; Mull L; Foreman B
J Gastrointest Cancer; 2007; 38(2-4):154-6. PubMed ID: 19089671
[TBL] [Abstract][Full Text] [Related]
27. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
28. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
Ranieri G; Gadaleta-Caldarola G; Goffredo V; Patruno R; Mangia A; Rizzo A; Sciorsci RL; Gadaleta CD
Curr Med Chem; 2012; 19(7):938-44. PubMed ID: 22214462
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Gollob JA
Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
[TBL] [Abstract][Full Text] [Related]
30. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
Messmer D; Fecteau JF; O'Hayre M; Bharati IS; Handel TM; Kipps TJ
Blood; 2011 Jan; 117(3):882-9. PubMed ID: 21079155
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
32. The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication.
Michaelis M; Paulus C; Löschmann N; Dauth S; Stange E; Doerr HW; Nevels M; Cinatl J
Cell Mol Life Sci; 2011 Mar; 68(6):1079-90. PubMed ID: 20803231
[TBL] [Abstract][Full Text] [Related]
33. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
Cheng H; Kari G; Dicker AP; Rodeck U; Koch WJ; Force T
Circ Res; 2011 Dec; 109(12):1401-9. PubMed ID: 21998323
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.
Zhao W; Gu YH; Song R; Qu BQ; Xu Q
Leukemia; 2008 Jun; 22(6):1226-33. PubMed ID: 18337760
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
[TBL] [Abstract][Full Text] [Related]
36. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
[TBL] [Abstract][Full Text] [Related]
37. Biological evaluation of a novel sorafenib analogue, t-CUPM.
Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor.
Kernt M; Liegl RG; Rueping J; Neubauer AS; Haritoglou C; Lackerbauer CA; Eibl KH; Ulbig MW; Kampik A
Growth Factors; 2010 Jun; 28(3):211-20. PubMed ID: 20166888
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
Heravi M; Tomic N; Liang L; Devic S; Holmes J; Deblois F; Radzioch D; Muanza T
Anticancer Drugs; 2012 Jun; 23(5):525-33. PubMed ID: 22357220
[TBL] [Abstract][Full Text] [Related]
40. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
Moreno-Vinasco L; Gomberg-Maitland M; Maitland ML; Desai AA; Singleton PA; Sammani S; Sam L; Liu Y; Husain AN; Lang RM; Ratain MJ; Lussier YA; Garcia JG
Physiol Genomics; 2008 Apr; 33(2):278-91. PubMed ID: 18303084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
